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Objective: To evaluate long-term renal outcomes after open type IV
thoracoabdominal aneurysm (TAAA) repair.
Design: Retrospective analysis of a prospectively collected database of
consecutive operated non-ruptured type IV TAAAs (2007-2011).
Methods: Renal function was analysed by serum creatinine concentra-
tion, estimated glomerular ﬁltration rate (eGFR) and Kidney Disease
Outcomes Quality Initiative (KDOQI) stage. The primary outcome was
the change in creatinine concentration from before surgery to deﬁned
time points after surgery: peak postoperative; discharge; at follow-up (>1
year postoperatively). Secondary outcomes were change in eGFR, change
in KDOQI stage, dialysis requirement, and 30-day mortality.
Results: Between 2007 and 2011, 53 open type IV TAAA repairs
were performed. Median creatinine levels signiﬁcantly increased in the
immediate postoperative period, but returned to baseline by discharge.
Thirteen patients (28.2%) had an improvement in follow-up eGFR of at
least 20% compared with pre-operative eGFR or improved by one KDOQI
stage. Twelve patients (26.1%) had a decline in eGFR of at least 20% or one
KDOQI stage at follow-up. Three patients (7.5%) required temporary dial-
ysis and one patient (1.9%) required permanent dialysis. The 30-day
mortality was 1.9%.
Conclusions: This study demonstrates acceptable renal outcomes
following open type IV TAAA repair. Open type IV repair remains the stan-
dard against which newer techniques should be compared.
On-label Use of Commercially-available Abdominal Endografts for
Para-anastomotic Aneurysms and Pseudoaneurysms after Infrarenal
Abdominal Aortic Aneurysm Open Repair
Tshomba Y., Mascia D., Kahlberg A., Marone E.M., Melissano G.,
Chiesa R. Eur J Vasc Endovasc Surg 2013;46:657-66.
Objectives: To analyze feasibility and outcomes of endovascular
aortic repair (EVAR) with a strictly on-label use of abdominal aortic endog-
rafts (OnL-EVAR) to treat para-anastomotic aneurysms (PAAs) and pseu-
doaneurysms (PSAs) after infrarenal abdominal aortic aneurysm open
repair (OR).
Methods: The data of all consecutive patients treated between 1999
and 2012 for non-infected abdominal PAAs and PSAs at our center were
prospectively collected. All cases ﬁt for EVAR based on the instructions
for use of a series of abdominal aortic endografts commercially available
during the study period were scheduled for OnL-EVAR regardless of
patients' surgical risk. Any patients unﬁt for OnL-EVAR underwent OR
or other complex endovascular techniques.
Results: One hundred and forty-three patients were collected; 78
underwent OR and 65 endovascular repair with different strategies. Coil
embolization, hybrid, and chimney/periscope grafts techniques were
limited to seven patients unﬁt both for OR and OnL-EVAR. Inclusion
criteria for OnL-EVAR were reached in 58 patients for an overall OnL-
EVAR feasibility of approximately 40% (21% for PAAs and 55% for PSAs).
In particular, OnL-EVAR feasibility was 19% in case of involvement of prox-
imal aortic anastomosis, 71% for distal aortic anastomosis, and 80% for iliac
arteries. Overall, 25 aortouniiliac and 11 bifurcated implants were per-
formed, single proximal aortic cuffs were used in 10 patients, and iliac exten-
sion in 12. Primary technical success was 98% without perioperative
mortality. At a median follow-up of 67 months (range: 1-144 months),
cumulative aneurysm-related mortality was 7%, endograft migration 7%,
and reintervention was 17%. Life-table analysis showed actuarial survival
and freedom from aneurysm-related death at 1, 3, and 5 years of 100%,
98%, and 95%, and of 100%, 98%, and 95%, respectively. Freedom from
aortic reintervention or open conversion at 1, 3, and 5 years was 94%,
90%, and 85%.1722Conclusions: Feasibility of OnL-EVAR was limited for PAAs and
PSAs, with a rate that was lower than 20% in case of involvement of prox-
imal aortic anastomosis. Aortouniiliac conﬁguration was the most
commonly feasible implant and, despite strict on-label use of abdominal
devices, the rate of late complications and reinterventions was high.
Prevalence of Severe Subclinical Coronary Artery Disease on Cardiac
CT and MRI in Patients with Extra-cardiac Arterial Disease
den Dekker M.A.M., van den Dungen J.J.A.M., Tielliu I.F.J., Tio R.A.,
Jaspers M.M.J.J.R., Oudkerk M., Vliegenthart R. Eur J Vasc Endovasc
Surg 2013;46:680-9.
Objective: Patients with extra-cardiac arterial disease (ECAD) are at
high risk of coronary artery disease (CAD). Prevalence of silent, signiﬁcant
CAD in patients with stenotic or aneurysmal ECAD was examined. Early
detection and treatment may reduce CAD mortality in this high-risk group.
Materials and methods: ECAD patients without cardiac complaints
underwent computed tomography (CT) for calcium scoring, coronary CT
angiography (cCTA) if calcium score was 1,000 or under, and adenosine
perfusion magnetic resonance imaging (APMR) if there was no left main
stenosis. Signiﬁcant CAD was deﬁned as calcium score over 1000, cCTA-
detected coronary stenosis of at least 50% lumen diameter, and/or
APMR-detected inducible myocardial ischemia. In cases of left main
stenosis (or equivalent) or myocardial ischemia, patients were referred to
a cardiologist.
Results: The prevalence of signiﬁcant CAD was 56.8% (95% CI
47.5 to 66.0). One-hundred and eleven patients were included. Eighty-
four patients (76%) had stenotic ECAD, and 27 (24%) had aneurysmal
disease. In patients with stenotic ECAD, signiﬁcant coronary stenosis
was present in 32 (38%) and inducible ischemia in eight (12%). Corre-
sponding results in aneurysmal ECAD were eight (30%) and two (11%),
respectively (P for difference >.05). Sixteen (19%) patients with stenotic
and six (22%) with aneurysmal ECAD were referred to a cardiologist,
with subsequent cardiac intervention in seven (44%) and three (50%),
respectively (both P >.05).
Conclusions: Patients with stenotic or aneurysmal ECAD have a high
prevalence of silent, signiﬁcant CAD.
Systematic Review of Home-based Exercise Programmes for
Individuals with Intermittent Claudication
Al-Jundi W., Madbak K., Beard J.D., Nawaz S., Tew G.A. Eur J Vasc
Endovasc Surg 2013;46:690-706.
We aimed to conduct a systematic review of the evidence for struc-
tured, home-based exercise programmes (HEPs) in patients with inter-
mittent claudication. The Medline, PsycINFO, EMBASE, and
Cochrane databases were searched up to April 2013 for terms related
to walking, self-management, and intermittent claudication. Descrip-
tive, methodological and outcome data were extracted from eligible
articles. Trial quality was assessed using the GRADE system. Seventeen
studies were included with 1457 participants. Six studies compared
HEPs with supervised exercise training, ﬁve compared HEPs with usual
care/observation control, and seven evaluated HEPs in a single-group
design. Trial heterogeneity prevented meta-analysis. Nevertheless, there
was “low-level” evidence that HEPs can improve walking capacity and
quality of life in patients with intermittent claudication when compared
with baseline or in comparison to usual care/observation control. In
addition, improvements with HEPs may be inferior to those evoked
by supervised exercise training. Considerable uncertainty exists
regarding the long-term clinical and cost effectiveness of HEPs in
patients with intermittent claudication. Thus, more robust trials are
needed to build evidence about these interventions. Nevertheless, clini-
cians should consider using structured interventions to promote self-
managed walking in patients with intermittent claudication, as opposed
